Skip to content
Top Globe News – Lifestyle
Author:
HCW Biologics Inc.
HCW Biologics Announces Pricing of $1.5 Million Private Placement
September 24, 2026
HCW11-006 CAR-T Reagent Commercialized by HCW Biologics & Akron Biotech
September 8, 2026
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
September 2, 2026
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
August 29, 2026
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
August 14, 2026
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
July 29, 2026
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
July 23, 2026
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
June 30, 2026
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
June 26, 2026
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
June 16, 2026
1
2
Next Page
→